EFFECTIVENESS OF SOFOSBUVIR DRUG IN THE TREATMENT OF HEPATITIS C INFECTION IN POST RENAL TRANSPLANT PATIENT
Dr. Abel Abraham Thomas* and Ms. Alfiya Ali
Hepatitis C is an infection caused by the Hepatitis C virus that attacks the liver and leads to inflammation. Being a communicable disease Hepatitis C has now become of the major reason for morbidity and mortality. The evidence suggests that chronic hepatitis c plays a detrimental role in survival among patients on maintenance dialysis or renal transplant recipient promotes the antiviral treatment of hepatitis c virus (HCV) among chronic kidney disease patients. Interferon based regimens have provided limited efficacy and safety among chronic kidney disease patients, whereas the advent of new direct acting antiviral for the treatment of hepaitisc (launched over the past 5 years) have given the opportunity to reach sustained virologic response rate of 90% for many patient groups. Sofusbovir has high efficacy in treating HCV in patients who were counteracted to the drug interferon. The viral load of the patients shows almost undetectable after 4weeks of treatment. It is also efficient in treating all genotype. Thus, the antiviral regimens based on direct acting antivirals promise to play a pivotal role in the eradication of hepatitis c among kidney disease patients. Direct acting antiviral are very expensive; in an era of cost containment this is a crucial point either in developed and developing countries.
Keywords: Hepatitis C, Anti Viral, Ribavirin, Interferon, Viral Load, Direct-Acting Antiviral, Sobosfovir.
[Full Text Article]